1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02756650
- Locations
- 🇹🇷
Novartis Investigative Site, Istanbul, Turkey
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
- Conditions
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 440
- Registration Number
- NCT02753686
- Locations
- 🇨🇦
Novartis Investigative Site, Quebec, Canada
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1660
- Registration Number
- NCT02752776
- Locations
- 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02750592
- Locations
- 🇯🇵
Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan
Study of Secukinumab With 2 mL Pre-filled Syringes
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT02748863
- Locations
- 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: SecukinumabBiological: Adalimumab
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 853
- Registration Number
- NCT02745080
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT02740270
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
- Conditions
- Advanced or Metastatic ER+ Breast Cancer
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02734615
- Locations
- 🇺🇸
MD Anderson Cancer Center SC - LSZ102X2101, Houston, Texas, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT02732119
- Locations
- 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
- Conditions
- Axial Psoratic Arthritis
- Interventions
- Biological: Secukinumab
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 503
- Registration Number
- NCT02721966
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom